Fulcrum Therapeutics, Inc. filed a Form 8-K on August 10, 2026, disclosing that its Board of Directors appointed Chief Financial Officer Alan Musso as principal accounting officer, effective August 7, 2026, following the departure of Greg Tourangeau from that role.

Key Highlights

  • Departure confirmed: Greg Tourangeau, Vice President, Finance and principal accounting officer, ended his tenure in those roles on August 7, 2026.
  • New appointment: Alan Musso, Fulcrum's chief financial officer and principal financial officer, was appointed principal accounting officer effective August 7, 2026.
  • Board action: The Board of Directors made the appointment on August 9, 2026, according to the filing.
  • No additional compensation: The filing states Mr. Musso will not receive any additional compensation in connection with this appointment.
  • No arrangements disclosed: The filing states there is no arrangement or understanding between Mr. Musso and any other persons pursuant to which he was appointed.

Fulcrum CFO Alan Musso Takes On Principal Accounting Officer Role

Fulcrum Therapeutics, Inc. (Nasdaq Global Market: FULC) reported the change in a current report filed under Item 5.02, which covers departures and appointments of certain officers. The departure of Greg Tourangeau had been previously disclosed in a Form 8-K filed on June 11, 2026, at which time the company noted that Tourangeau and Fulcrum had "mutually agreed" that he would leave on a date to be determined. The August 10, 2026 filing confirms that date as August 7, 2026.

Alan Musso, who already serves as Fulcrum's chief financial officer and principal financial officer, assumes the additional designation of principal accounting officer as of Mr. Tourangeau's departure date. The filing notes that biographical information for Mr. Musso is available in Fulcrum's definitive proxy statement on Schedule 14A, filed with the SEC on April 30, 2026, and incorporated by reference into this report.

According to the filing, there are no family relationships among any of Fulcrum's directors or executive officers and Mr. Musso, and Mr. Musso does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The report was signed by Alex C. Sapir, President and Chief Executive Officer, on August 10, 2026.

What Was Disclosed

The filing confirms Greg Tourangeau's departure as principal accounting officer on August 7, 2026, and the Board's appointment of CFO Alan Musso to that role on the same date, with no additional compensation tied to the new designation.